Volume : 13, Issue : 09, September – 2026
Title:
IMPACT OF SCHEDULE M AMENDMENTS ON PHARMACEUTICAL MANUFACTURING PROCESSES IN INDIA.
Authors :
Akulapelly Thrisha* & G.Kamal Yadav
Abstract :
The recent amendments to Schedule M of the Drugs and Cosmetics Rules, 1945 represent a significant regulatory milestone aimed at strengthening India’s pharmaceutical manufacturing framework in alignment with global quality standards such as WHO-GMP and PIC/S guidelines. These revisions emphasize enhanced Good Manufacturing Practices (GMP), risk-based approaches, and data integrity requirements to ensure product quality, patient safety, and international regulatory compliance.
This study examines the impact of Schedule M amendments on pharmaceutical manufacturing processes in India, focusing on changes in facility design, documentation practices, quality management systems, validation protocols, and technology adoption. The research further explores the implications for small and medium enterprises (SMEs), cost considerations, compliance timelines, and the transition challenges faced by industry stakeholders. By comparing the pre- and post-amendment frameworks, the analysis highlights the potential improvements in manufacturing robustness, reduction in product recalls, and increased global competitiveness of Indian pharmaceutical exports.
The findings suggest that while the revised Schedule M enhances regulatory oversight and manufacturing excellence, effective implementation will depend on capacity building, regulatory harmonization, and industry readiness. The amendments are expected to transform the Indian pharmaceutical sector into a more quality-driven and globally trusted industry.
Keywords: Schedule M amendments, Good Manufacturing Practices (GMP), pharmaceutical manufacturing, regulatory compliance, quality management system (QMS), WHO-GMP alignment, data integrity, India, pharmaceutical industry, PIC/S standards
Cite This Article:
Please cite this article in press Akulapelly Thrisha et al., Impact Of Schedule M Amendments On Pharmaceutical Manufacturing Processes In India..,. Indo Am. J. P. Sci, 2026; 13(09).
REFERENCES:
1. Central Drugs Standard Control Organisation (CDSCO). (2024). Revised Schedule M Guidelines for Good Manufacturing Practices. Ministry of Health and Family Welfare, Government of India.
2. Chaudhuri, S. (2005). The Indian Pharmaceutical Industry: Growth and Prospects. Oxford University Press.
3. Department of Pharmaceuticals. (2023). Annual Report 2022–23. Government of India.
4. Gupta, R., Patel, M., & Rao, S. (2019). Quality compliance trends in Indian pharmaceutical manufacturing. Journal of Regulatory Science, 7(3), 22–31.
5. Jain, A., & Mehta, K. (2022). Data integrity challenges in Indian drug manufacturing. International Journal of Pharmaceutical Quality Assurance, 13(4), 245–253.
6. Kumar, V., Singh, D., & Rani, P. (2023). Advancing GMP compliance through risk-based approaches in India. Asian Journal of Pharmacy Practice, 16(2), 88–96.
7. Lalitha, N. (2018). Intellectual Property and Innovation: Indian Pharmaceutical Industry. Springer.
8. MoHFW. (2024). Gazette Notification on Revised Schedule M (Good Manufacturing Practices), 2024. Ministry of Health and Family Welfare, New Delhi.
9. Pharmaceuticals Export Promotion Council of India (Pharmexcil). (2024). Export Statistics 2023–24.
10. Press Information Bureau (PIB). (2024). India’s Pharmaceutical Sector Overview. Government of India.